| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Rabourn Amy Zaremba | Head of Fin. Quality Assurance | 2026-01-18 | 3,390 | $2.10 | $7.12kSell |
| Rabourn Amy Zaremba | Head of Fin. Quality Assurance | 2026-01-10 | 3,950 | $1.93 | $7.62kSell |
| Cam Gallagher | Director | 2025-12-29 | 81,000 | $1.98 | $160.30kBuy |
| Cam Gallagher | Director | 2025-12-29 | 83,000 | $1.97 | $163.43kBuy |
| Foundation Fighting Blindness Retinal Degeneration Fund | Director | 2025-12-09 | 4,000,000 | $2.15 | $8.60MSell |
| George Magrath | Chief Executive Officer | 2025-11-01 | 30,350 | $2.30 | $69.81kSell |
| George Magrath | Chief Executive Officer | 2025-11-01 | 30,350 | $2.30 | $69.81kSell |
| George Magrath | Chief Executive Officer | 2025-11-01 | 30,350 | $2.30 | $69.81kSell |
| Benjamin R. Yerxa | President | 2025-10-22 | 23,795 | $1.95 | $46.40kSell |
| Sean Ainsworth | Director | 2025-08-25 | 86,956 | $1.15 | $100.00kBuy |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Sungkee Chung | 237.51% | 163,800,000 | $375.10M | Insider |
| Sung Sook Park | 101.79% | 70,200,000 | $160.76M | Insider |
| Frank Ferraro | 37.70% | 26,000,000 | $59.54M | Insider |
| Inok Ahn | 20.30% | 14,000,000 | $32.06M | Insider |
| Chang Ho Ahn | 16.69% | 11,510,000 | $26.36M | Insider |
| Rexgene Biotech Co Ltd | 7.98% | 5,505,956 | $12.61M | Insider |
| Foundation Fighting Blindness Retinal Degeneration Fund | 7.96% | 5,492,171 | $12.58M | Insider |
| Perceptive Advisors LLC | 6.27% | 4,325,000 | $9.90M | Institution |
| Bios Capital Management LP | 5.34% | 3,683,429 | $8.44M | Institution |
| Nantahala Capital Management LLC | 4.85% | 3,345,923 | $7.66M | Institution |